Novo: Kalundborg's Rise

Novo Nordisk, a pharmaceutical giant based in Kalundborg, Denmark, experienced a period of unprecedented growth and economic impact due to its successful weight loss drugs Ozempic and Wegovy. This led to a significant influx of workers and investment in the region, transforming Kalundborg into a global hub for obesity treatment. However, the company’s rapid rise has been followed by challenges, including a dramatic stock price decline, layoffs, and increased competition from Eli Lilly. Novo’s reliance on a single active ingredient, semaglutide, and initial strategic missteps have contributed to these difficulties, alongside the expiration of patents and the emergence of cheaper generic versions. Despite setbacks, Kalundborg remains a key site for Novo’s expansion and investment, with ongoing construction and a growing international workforce, though local businesses face challenges due to Novo’s dominance.